Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Summary

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Small Cell Lung Cancer Metastatic or Locally Advanced
• Neuroendocrine Cancer
• Metastatic Neuroendocrine Prostate Cancer
• Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
• Metastatic Advanced Merkel Cell Carcinoma
• Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung
• Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
• Locally Advanced Neuroendocrine Prostate Cancer
• Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine
• Locally Advanced Merkel Cell Carcinoma
• Metastatic Large Cell Neuroendocrine Carcinoma of the Lung

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

SystImmune Inc.

Last updated on ClinicalTrials.gov

September 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites